18F-Fluorodeoxyglucose PET in Locally Advanced Non–small Cell Lung Cancer: From Predicting Outcomes to Guiding Therapy

Research output: Contribution to journalReview article


PET using 18-fluorodeoxyglucose (FDG) has become an important part of the work-up for non–small cell lung cancer (NSCLC). This article summarizes advancements in using FDG-PET for patients with locally advanced NSCLC treated with definitive radiation therapy (RT). This article discusses prognostication of outcome based on pretreatment or midtreatment PET metrics, using textural image features to predict treatment outcomes, and using PET to define RT target volumes and inform RT dose modifications. The role of PET is evolving and is moving toward using quantitative image information, with the overarching goal of individualizing therapy to improve outcomes for patients with NSCLC.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalPET Clinics
Issue number1
StatePublished - Jan 2020



  • Non–small cell lung cancer
  • PET
  • Radiation therapy

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this